VFA
MCRB icon

Valeo Financial Advisors’s Seres Therapeutics MCRB Stock Holding History

Valeo Financial Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12
Closed -$5K – 1267
2021
Q1 		$5K Hold
12
– – ﹤0.01% 1568
2020
Q4 		$6K Hold
12
– – ﹤0.01% 1334
2020
Q3 		$7K Buy
+12
New +$3.99K ﹤0.01% 1166

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Valeo Financial Advisors's MCRB Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Seres Therapeutics (MCRB) in Q2 2021, closing a stake of 12 shares — an estimated $5K sold.

Valeo Financial Advisors first reported a position in MCRB in Q3 2020 and held it in 3 quarters. The position peaked at $7K in Q3 2020. 146 funds tracked by Wall St. Rank hold MCRB as of Q2 2021.

  • Valeo Financial Advisors reported no remaining Seres Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 12 Seres Therapeutics shares in Q2 2021, an estimated $5K.
  • Valeo Financial Advisors first reported a position in Seres Therapeutics in Q3 2020 and held it in 3 quarters.
  • Valeo Financial Advisors's Seres Therapeutics position peaked at $7K in Q3 2020.
  • 146 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.